pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Register for your FREE ticket here: [link].

Drug Development 52

Drug Development Immunity Immunization 52

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a small molecule administered orally.

Chemotherapy 40

Chemotherapy Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a small molecule administered orally.

Chemotherapy 40

Chemotherapy Drug Development 40

European Pharmaceutical Review

NOVEMBER 7, 2023

Positive results for a combination treatment using the first Fc-silent investigational monoclonal antibody in pivotal clinical trials that is designed to block and bind to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), have been announced. The treatment is being evaluated in patients with upper GI adenocarcinomas.

Chemotherapy 97

Chemotherapy 97

European Pharmaceutical Review

JULY 5, 2022

Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer. Stomach cancer, also known as gastric cancer, is the fifth most common type of cancer worldwide – and the third most common cause of death from cancer.

Chemotherapy 88

Chemotherapy Dosage Labelling Compounding 88

pharmaphorum

JULY 6, 2021

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. HER-Vaxx is a B-cell activating cancer immunotherapy that consists of several B cell epitopes derived from the extracellular domain of HER2.

Vaccines 117

Vaccines Chemotherapy Immunity Immunization 117

pharmaphorum

AUGUST 2, 2022

AbbVie and Sosei Heptares will initially focus on developing up to three GPCR-modulating small-molecule drugs to the point at which they are ready to start clinical trials in humans, whereupon AbbVie has opt-in rights to take them further. The new agreement follows earlier alliances including one worth up to $2.6

Immunity 97

Immunity Immunization 97

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Drug Development 52

Drug Development 52

European Pharmaceutical Review

NOVEMBER 17, 2022

In pre-clinical studies, this binding interaction caused cancer cell death by activating antibody-dependent cellular toxicity and complement-dependent cytotoxicity immune system pathways. Gastric and GEJ cancers still have very limited treatment options available for patients with an advanced diagnosis.”. expression in ? “I

Immunity 80

Immunity Immunization Hospitals 80

European Pharmaceutical Review

JANUARY 23, 2023

For the first time, a clinical study in the first-line setting for mPDAC demonstrated superior overall survival (OS) and progression-free survival (PFS) for an investigational regimen when compared to standard of care treatment with nab-paclitaxel and gemcitabine.”

Chemotherapy 89

Chemotherapy Labelling 89

pharmaphorum

JANUARY 12, 2021

Boehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight cancer using “dark antigens” in a deal worth up to €876 million ($1.07bn). This makes them good targets for targeted therapies that will attack cancer cells while leaving healthy cells alone.

Vaccines 80

Vaccines Immunity Immunization 80

European Pharmaceutical Review

NOVEMBER 4, 2022

Despite advances with targeted and immuno-oncology therapies, chemotherapies remain a cornerstone of cancer treatment for many tumour types – a reflection of their significant anti?tumour They are widely used to treat a variety of solid tumours, including prostate, lung, ovarian and breast cancer. tumour effects.

Chemotherapy 86

Chemotherapy Hospitals Packaging 86

Pharmaceutical Technology

JUNE 27, 2022

Turning Point Therapeutics has entered a strategic research and development alliance with the University of Texas MD Anderson Cancer Center (MD Anderson) to advance the evaluation of two of its investigational small molecules for precision cancer treatments. A kinase inhibitor, elzovantinib (TPX-0022) targets MET, CSF1R and SRC.

Chemotherapy 59

Chemotherapy Compounding 59

PharmaShots

APRIL 7, 2023

TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis Date: Apr 3, 2023 | Tags: TG Therapeutics, Briumvi, Ublituximab-xiiy, Multiple Sclerosis, Regulatory, EMA, CHMP BMS Receives EMA’s CHMP Positive Opinion of Breyanzi (lisocabtagene maraleucel) for (..)

Biosimilars 53

Biosimilars Immunity Immunization 53

PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

Biosimilars 40

Biosimilars Diabetes 40

European Pharmaceutical Review

MARCH 4, 2024

This growth is accompanied by a substantial number of clinical trials, with close to 20,000 active investigations, involving about 9,500 new biologic treatments. These actions occur at both the delivery site and other systemic locations, thereby promoting an immunogenic response that leads to cancer cell death. percent through 2027.

Vaccines 92

Vaccines Immunity Immunization Compounding 92

Pharmaceutical Technology

APRIL 24, 2023

As healthcare confronts challenges such as antimicrobial resistance and the spread of previously geographically constrained diseases as a result of climate change, research into natural products used in traditional medicine, referred to as ‘ethnopharmacology’, could help in finding new, clinically effective drugs.

Compounding 105

Compounding Chemotherapy 105

Pharmaceutical Technology

MAY 31, 2023

Fruquintinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 40

pharmaphorum

APRIL 14, 2021

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations. . KRAS is the most frequently mutated gene that causes cancer and is expressed in one in seven of all human metastatic cancers.

52

52

pharmaphorum

APRIL 26, 2022

Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology. The gut microbiome has long been linked to gastrointestinal conditions, such as inflammatory bowel disease and irritable bowel diseases, as well as obesity and type 2 diabetes.

Immunity 113

Immunity Immunization Diabetes Drug Development 113

pharmaphorum

JUNE 23, 2022

BRAF V600E mutations are seen in around 20 different types of cancer, said Novartis, which has previously won regulatory approvals for the combination as treatment for BRAF-mutated melanoma, non-small cell lung cancer (NSCLC) and thyroid cancers. billion to Novartis’ top-line last year. Tabrecta approved in Europe.

Chemotherapy 52

Chemotherapy 52

Pharmaceutical Technology

APRIL 12, 2023

The latest move is a result of the cancellation of a licensing agreement between Cancer Prevention Pharmaceuticals (CPP) and One-Two Therapeutics Assets. It is expected to focus on FAP patients with intact lower gastrointestinal anatomy. The new registration trial will be based on positive data obtained from the FAP-310 trial.

52

52

Board Vitals - Pharmacist

FEBRUARY 9, 2024

The Radiology Qualifying (Core) Exam is designed to evaluate a candidate’s core fund of knowledge and clinical judgment across practice domains of diagnostic radiology and integrated interventional radiology/diagnostic radiology.

52

52

pharmaphorum

MAY 4, 2022

The FDA has kicked off a priority review of AstraZeneca’s checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group of rare and aggressive gastrointestinal tumours. The post AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer appeared first on.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

MAY 14, 2021

BMS is setting up Zeposia as a first or second line therapy and noted clinical evidence that the drug reduces relapses and brain lesions compared with Biogen’s Avonex (interferon beta-1a). But NICE said in its guidance that the drug’s impact on disability progression was unclear from the clinical evidence presented by BMS’ Celgene unit.

97

97

Pharmaceutical Technology

FEBRUARY 19, 2023

Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Chemotherapy 40

Chemotherapy Diabetes Drug Development 40

pharmaphorum

DECEMBER 10, 2020

Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, adding an antibody-drug conjugate (ADC) platform led by a drug for a hard-to-treat form of breast cancer. The post Boehringer buys NBE for €1.18bn, adding cancer ADC expertise appeared first on.

Vaccines 57

Vaccines Immunity Immunization Drug Development 57

pharmaphorum

FEBRUARY 15, 2022

Armed with new clinical trial results, Amgen is expanding studies of its KRAS inhibitor Lumakras in pancreatic cancer, as it tries to extend the label for the first-in-class drug beyond its current use in non-small cell lung cancer (NSCLC).

Labelling 52

Labelling Chemotherapy 52

pharmaphorum

JULY 31, 2021

Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position with an EU approval in the post-surgery (adjuvant) setting. The post BMS claims first EU okay for adjuvant oesophageal cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy 52

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company also develops and markets generic biosimilar products.

Biosimilars 40

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 40

pharmaphorum

FEBRUARY 8, 2021

There are a range of MS drugs on the market but Zeposia does not have the common unpleasant gastrointestinal side effects that can occur with Biogen’s Tecfidera. Zeposia was generally well tolerated across both head-to-head phase 3 clinical trials, with 90% of patients completing the studies, the company added.

Hospitals 64

Hospitals 64

Pharma Marketing Network

MARCH 2, 2022

” IQVIA measures its success of novel molecules in clinical trials by clinical development productivity, which experienced a decline across all disease areas in 2021, except for, of course, vaccines and in cardiovascular. 3 therapeutic areas with the most growth are oncology, gastrointestinal disorders, and neurology.

Vaccines 52

Vaccines 52

RX Note

JUNE 18, 2023

The most common adverse effects of metformin are gastrointestinal disturbances, including anorexia, nausea, abdominal discomfort and diarrhoea. These gastrointestinal side effects are usually transient and can be minimised by Administering the drug with or after food. The use of pioglitazone may increase the risk of bladder cancer.

Diabetes 52

Diabetes Dosage Hospitals 52

European Pharmaceutical Review

MARCH 24, 2023

He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space. Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis. How does pegozafermin work in potentially treating NASH?

Drug Development 88

Drug Development 88

PharmD Live

MARCH 30, 2022

The patient’s history included cardiac disease and a recently diagnosed cancer. Ultimately, the person was diagnosed with digoxin toxicity due to renal complications of their newly diagnosed renal cancer and taking herbal preparation for cancer rather than chemotherapy. Journal of Evaluation in Clinical Practice.

Hospitals 52

Hospitals Inpatient Chemotherapy 52

RX Note

NOVEMBER 3, 2023

Breastfeeding is associated with child health benefits including reduced risk for acute otitis media, gastrointestinal and other infections, and may be associated with reduced risk for atopic dermatitis and asthma. Maternal health benefits may include reduced risk of some chronic diseases and cancer.

Hospitals 52

Hospitals Community Pharmacies 52